BioSpace News Archive

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) (“FSD Pharma” or the “Company”) today announced the sale of 5.0 million common shares of Pharmadrug Inc. (CSE:BUZZ) (formerly Aura Health) in a privately negotiated transaction at C$0.08 per share for cash proceeds of C$400,000. Under the terms of the sale, the buyer has the option through June 26, 2020 to purchase

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88).

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that Sapphire Biotech, Inc.

OncoSec Medical Incorporated (the “Company” or “OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it will present new pre-clinical data demonstrating the utility of OncoSec’s next-generation product candidate, TAVO PLUS (enhanced interleukin-12 or “IL

FUJIFILM Medical Systems U.S.A. Inc ., a leading provider of enterprise imaging and informatics solutions, and part of the greater Fujifilm Healthcare portfolio, today announced that three more diagno

Bausch Health Companies Inc. announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Goldman Sachs Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. EDT.

Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced the appointments of Carlos Paya, M.D., Ph.D., as Chair of the Scientific Advisory Board and Lainie Martin, M.D., as a member of the Clinical Advisory Board.

Majority of 23 peptide epitopes selected by IMV demonstrated robust antibody responses in an animal model after first and second dose in DPX formulation without any additional adjuvant

Patent allowance follows compelling Phase II data showing Namodenoson resolved all cases of NASH after 12 weeks of treatment, and it reduced hepatic fibrosis and steatosis in NAFLD and NASH patients

Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with amplifications and MET fusions, including glioblastoma multiforme